Lupin Limited — Important, 17-07-2025: Updates

Lupin's Pithampur Unit-2 manufacturing facility received a Form-483 with four observations following a US FDA inspection. The company is promptly addressing these findings and will respond to the FDA. Lupin emphasizes its dedication to quality and cGMP standards across all its sites. While such observations can lead to future scrutiny, the company's swift action to resolve issues is crucial for maintaining compliance and ensuring continued product flow from this key facility.